M&A Deal Summary

Rosetta Genomics Acquires PersonalizeDx

On April 9, 2015, Rosetta Genomics acquired life science company PersonalizeDx from Prelude for 2M USD

Acquisition Highlights
  • This is Rosetta Genomics’ 1st transaction in the Life Science sector.
  • This is Rosetta Genomics’ largest (disclosed) transaction.
  • This is Rosetta Genomics’ 1st transaction in the United States.
  • This is Rosetta Genomics’ 1st transaction in California.
Investment Fate
  • PersonalizeDx was divested to a consortium of strategic buyers in 2018 for 1M USD.

M&A Deal Summary
Date 2015-04-09
Target PersonalizeDx
Sector Life Science
Buyer(s) Rosetta Genomics
Sellers(s) Prelude
Deal Type Divestiture
Deal Value 2M USD

Target

PersonalizeDx

Lake Forest, California, United States
PersonalizeDx Labs provides as a service molecular tests in pharmacogenomics, genetic disorders, oncology and infectious disease which will serve as a valuable aid for clinicians in diagnosing patients early and enable appropriate therapeutic intervention to enhance patient care.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Rosetta Genomics

Rehovot, Israel
Category Company
Founded 2000
Sector Life Science
Employees52
Revenue 1M USD (2014)
DESCRIPTION

Rosetta Genomics Ltd. is a developer and provider of microRNA-based and other molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2018-03-05 PersonalizeDx

Lake Forest, California, United States

PersonalizeDx Labs provides as a service molecular tests in pharmacogenomics, genetic disorders, oncology and infectious disease which will serve as a valuable aid for clinicians in diagnosing patients early and enable appropriate therapeutic intervention to enhance patient care.

Sell $1M

Seller(S) 1

SELLER

Prelude

Laguna Hills, California, United States
Category Company
Sector Life Science
DESCRIPTION

Prelude Corp. is a developer of prognostic test for ductal carcinoma in situ (DCIS). Prelude’s proprietary risk algorithms combine results from a panel of biomarkers that reveal a patient’s DCIS biology.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal